nodes	percent_of_prediction	percent_of_DWPC	metapath
Prochlorperazine—Edema cerebral—Carmustine—lymphatic system cancer	0.0506	0.0506	CcSEcCtD
Prochlorperazine—Consciousness abnormal—Vincristine—lymphatic system cancer	0.0431	0.0431	CcSEcCtD
Prochlorperazine—Brain oedema—Carmustine—lymphatic system cancer	0.0274	0.0274	CcSEcCtD
Prochlorperazine—Sudden death—Teniposide—lymphatic system cancer	0.0272	0.0272	CcSEcCtD
Prochlorperazine—Megacolon—Methotrexate—lymphatic system cancer	0.0221	0.0221	CcSEcCtD
Prochlorperazine—Amenorrhoea—Mechlorethamine—lymphatic system cancer	0.0215	0.0215	CcSEcCtD
Prochlorperazine—Deep vein thrombosis—Fludarabine—lymphatic system cancer	0.0201	0.0201	CcSEcCtD
Prochlorperazine—Cyanosis—Teniposide—lymphatic system cancer	0.0197	0.0197	CcSEcCtD
Prochlorperazine—Ileus paralytic—Vincristine—lymphatic system cancer	0.0173	0.0173	CcSEcCtD
Prochlorperazine—Altered state of consciousness—Vincristine—lymphatic system cancer	0.0162	0.0162	CcSEcCtD
Prochlorperazine—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.0152	0.0152	CcSEcCtD
Prochlorperazine—Sudden death—Mitoxantrone—lymphatic system cancer	0.0142	0.0142	CcSEcCtD
Prochlorperazine—Pancytopenia—Mechlorethamine—lymphatic system cancer	0.0113	0.0113	CcSEcCtD
Prochlorperazine—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.0112	0.0112	CcSEcCtD
Prochlorperazine—Coma—Fludarabine—lymphatic system cancer	0.0112	0.0112	CcSEcCtD
Prochlorperazine—Jaundice—Mechlorethamine—lymphatic system cancer	0.0103	0.0103	CcSEcCtD
Prochlorperazine—Retinal disorder—Methotrexate—lymphatic system cancer	0.0102	0.0102	CcSEcCtD
Prochlorperazine—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.00986	0.00986	CcSEcCtD
Prochlorperazine—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.00897	0.00897	CcSEcCtD
Prochlorperazine—Pancytopenia—Teniposide—lymphatic system cancer	0.0083	0.0083	CcSEcCtD
Prochlorperazine—Amenorrhoea—Mitoxantrone—lymphatic system cancer	0.00829	0.00829	CcSEcCtD
Prochlorperazine—Gait disturbance—Carmustine—lymphatic system cancer	0.00803	0.00803	CcSEcCtD
Prochlorperazine—Pulmonary embolism—Carmustine—lymphatic system cancer	0.00783	0.00783	CcSEcCtD
Prochlorperazine—Dysphagia—Fludarabine—lymphatic system cancer	0.00768	0.00768	CcSEcCtD
Prochlorperazine—Gait disturbance—Vincristine—lymphatic system cancer	0.00766	0.00766	CcSEcCtD
Prochlorperazine—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00739	0.00739	CcSEcCtD
Prochlorperazine—Pancytopenia—Fludarabine—lymphatic system cancer	0.00729	0.00729	CcSEcCtD
Prochlorperazine—Coma—Carmustine—lymphatic system cancer	0.00716	0.00716	CcSEcCtD
Prochlorperazine—Sudden death—Methotrexate—lymphatic system cancer	0.00709	0.00709	CcSEcCtD
Prochlorperazine—Gynaecomastia—Carmustine—lymphatic system cancer	0.00701	0.00701	CcSEcCtD
Prochlorperazine—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.00693	0.00693	CcSEcCtD
Prochlorperazine—Coma—Vincristine—lymphatic system cancer	0.00683	0.00683	CcSEcCtD
Prochlorperazine—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00674	0.00674	CcSEcCtD
Prochlorperazine—Infection—Mechlorethamine—lymphatic system cancer	0.0067	0.0067	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.0066	0.0066	CcSEcCtD
Prochlorperazine—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00655	0.00655	CcSEcCtD
Prochlorperazine—Arrhythmia—Teniposide—lymphatic system cancer	0.00625	0.00625	CcSEcCtD
Prochlorperazine—Deep vein thrombosis—Methotrexate—lymphatic system cancer	0.00596	0.00596	CcSEcCtD
Prochlorperazine—Eruption—Methotrexate—lymphatic system cancer	0.0059	0.0059	CcSEcCtD
Prochlorperazine—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00581	0.00581	CcSEcCtD
Prochlorperazine—Agitation—Teniposide—lymphatic system cancer	0.0056	0.0056	CcSEcCtD
Prochlorperazine—Arrhythmia—Fludarabine—lymphatic system cancer	0.00549	0.00549	CcSEcCtD
Prochlorperazine—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.00546	0.00546	CcSEcCtD
Prochlorperazine—Leukopenia—Teniposide—lymphatic system cancer	0.00545	0.00545	CcSEcCtD
Prochlorperazine—Pancytopenia—Bleomycin—lymphatic system cancer	0.00535	0.00535	CcSEcCtD
Prochlorperazine—Urinary retention—Vincristine—lymphatic system cancer	0.00516	0.00516	CcSEcCtD
Prochlorperazine—Cardiac arrest—Vincristine—lymphatic system cancer	0.00516	0.00516	CcSEcCtD
Prochlorperazine—Cyanosis—Methotrexate—lymphatic system cancer	0.00513	0.00513	CcSEcCtD
Prochlorperazine—Oedema—Teniposide—lymphatic system cancer	0.00497	0.00497	CcSEcCtD
Prochlorperazine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00497	0.00497	CcSEcCtD
Prochlorperazine—Infection—Teniposide—lymphatic system cancer	0.00494	0.00494	CcSEcCtD
Prochlorperazine—Agitation—Fludarabine—lymphatic system cancer	0.00492	0.00492	CcSEcCtD
Prochlorperazine—Dysphagia—Carmustine—lymphatic system cancer	0.00492	0.00492	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00487	0.00487	CcSEcCtD
Prochlorperazine—Leukopenia—Fludarabine—lymphatic system cancer	0.00479	0.00479	CcSEcCtD
Prochlorperazine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Prochlorperazine—Cough—Fludarabine—lymphatic system cancer	0.00467	0.00467	CcSEcCtD
Prochlorperazine—Pancytopenia—Carmustine—lymphatic system cancer	0.00467	0.00467	CcSEcCtD
Prochlorperazine—Hypotension—Teniposide—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Prochlorperazine—Convulsion—Fludarabine—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Prochlorperazine—Pancytopenia—Vincristine—lymphatic system cancer	0.00446	0.00446	CcSEcCtD
Prochlorperazine—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00443	0.00443	CcSEcCtD
Prochlorperazine—Dyspnoea—Teniposide—lymphatic system cancer	0.00443	0.00443	CcSEcCtD
Prochlorperazine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Prochlorperazine—Oedema—Fludarabine—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Prochlorperazine—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.00434	0.00434	CcSEcCtD
Prochlorperazine—Infection—Fludarabine—lymphatic system cancer	0.00434	0.00434	CcSEcCtD
Prochlorperazine—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00432	0.00432	CcSEcCtD
Prochlorperazine—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Prochlorperazine—Apnoea—Methotrexate—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Prochlorperazine—Rash—Mechlorethamine—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Prochlorperazine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Prochlorperazine—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00421	0.00421	CcSEcCtD
Prochlorperazine—Weight increased—Mitoxantrone—lymphatic system cancer	0.00416	0.00416	CcSEcCtD
Prochlorperazine—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Prochlorperazine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00407	0.00407	CcSEcCtD
Prochlorperazine—Jaundice—Mitoxantrone—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Prochlorperazine—Urticaria—Teniposide—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Prochlorperazine—Body temperature increased—Teniposide—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Prochlorperazine—Erythema—Bleomycin—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Prochlorperazine—Dyspnoea—Fludarabine—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Prochlorperazine—Oedema peripheral—Carmustine—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Prochlorperazine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.0038	0.0038	CcSEcCtD
Prochlorperazine—Constipation—Fludarabine—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Prochlorperazine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00366	0.00366	CcSEcCtD
Prochlorperazine—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.00363	0.00363	CcSEcCtD
Prochlorperazine—Pruritus—Teniposide—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Prochlorperazine—Arrhythmia—Carmustine—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Prochlorperazine—Leukopenia—Bleomycin—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Prochlorperazine—Body temperature increased—Fludarabine—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Prochlorperazine—Erythema—Carmustine—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Prochlorperazine—Cough—Bleomycin—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Prochlorperazine—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Prochlorperazine—Coma—Methotrexate—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Prochlorperazine—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Prochlorperazine—Gynaecomastia—Methotrexate—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Prochlorperazine—Vision blurred—Carmustine—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Prochlorperazine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Prochlorperazine—Tremor—Carmustine—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Prochlorperazine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Prochlorperazine—Oedema—Bleomycin—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Prochlorperazine—Erythema—Mitoxantrone—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Prochlorperazine—Infection—Bleomycin—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Prochlorperazine—Agitation—Carmustine—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Prochlorperazine—Rash—Teniposide—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Prochlorperazine—Dermatitis—Teniposide—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Prochlorperazine—Headache—Teniposide—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Prochlorperazine—Pruritus—Fludarabine—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Prochlorperazine—Leukopenia—Carmustine—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Prochlorperazine—Agitation—Vincristine—lymphatic system cancer	0.003	0.003	CcSEcCtD
Prochlorperazine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.003	0.003	CcSEcCtD
Prochlorperazine—Photosensitivity—Methotrexate—lymphatic system cancer	0.003	0.003	CcSEcCtD
Prochlorperazine—Hypotension—Bleomycin—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Prochlorperazine—Convulsion—Carmustine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Prochlorperazine—Leukopenia—Vincristine—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Prochlorperazine—Dyspnoea—Bleomycin—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Prochlorperazine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Prochlorperazine—Convulsion—Vincristine—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Prochlorperazine—Oedema—Carmustine—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Prochlorperazine—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Prochlorperazine—Cough—Mitoxantrone—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Prochlorperazine—Infection—Carmustine—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Prochlorperazine—Convulsion—Mitoxantrone—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Prochlorperazine—Rash—Fludarabine—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Prochlorperazine—Dermatitis—Fludarabine—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Prochlorperazine—Headache—Fludarabine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Prochlorperazine—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Prochlorperazine—Oedema—Vincristine—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Prochlorperazine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Prochlorperazine—Infection—Vincristine—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Prochlorperazine—Hypotension—Carmustine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Prochlorperazine—Oedema—Mitoxantrone—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Prochlorperazine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Prochlorperazine—Infection—Mitoxantrone—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Prochlorperazine—Urticaria—Bleomycin—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Prochlorperazine—Body temperature increased—Bleomycin—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Prochlorperazine—Insomnia—Carmustine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Prochlorperazine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Prochlorperazine—Hypotension—Vincristine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Prochlorperazine—Dyspnoea—Carmustine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Prochlorperazine—Somnolence—Carmustine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Prochlorperazine—Hypotension—Mitoxantrone—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Prochlorperazine—Insomnia—Vincristine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Prochlorperazine—Constipation—Carmustine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Prochlorperazine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Prochlorperazine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Prochlorperazine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Prochlorperazine—Constipation—Vincristine—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Prochlorperazine—Asthma—Methotrexate—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Prochlorperazine—Pruritus—Bleomycin—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Prochlorperazine—Eosinophilia—Methotrexate—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Prochlorperazine—Constipation—Mitoxantrone—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Prochlorperazine—Body temperature increased—Carmustine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Prochlorperazine—Pancytopenia—Methotrexate—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Prochlorperazine—Body temperature increased—Vincristine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Prochlorperazine—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Prochlorperazine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Prochlorperazine—Urticaria—Mitoxantrone—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Prochlorperazine—Hypersensitivity—Carmustine—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Prochlorperazine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Prochlorperazine—Drowsiness—Methotrexate—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Prochlorperazine—Rash—Bleomycin—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Prochlorperazine—Dermatitis—Bleomycin—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Prochlorperazine—Hypersensitivity—Vincristine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Prochlorperazine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Prochlorperazine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Prochlorperazine—Dizziness—Carmustine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Prochlorperazine—Dizziness—Vincristine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Prochlorperazine—Rash—Carmustine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Prochlorperazine—Dermatitis—Carmustine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Prochlorperazine—Headache—Carmustine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Prochlorperazine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Prochlorperazine—Rash—Vincristine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Prochlorperazine—Dermatitis—Vincristine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Prochlorperazine—Headache—Vincristine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Prochlorperazine—Rash—Mitoxantrone—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Prochlorperazine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Prochlorperazine—Headache—Mitoxantrone—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Prochlorperazine—Erythema—Methotrexate—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Prochlorperazine—Vision blurred—Methotrexate—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Prochlorperazine—Leukopenia—Methotrexate—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Prochlorperazine—Cough—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Prochlorperazine—Convulsion—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Prochlorperazine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Prochlorperazine—Infection—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Prochlorperazine—Skin disorder—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Prochlorperazine—Hypotension—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Prochlorperazine—Insomnia—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Prochlorperazine—Dyspnoea—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Prochlorperazine—Somnolence—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Prochlorperazine—Urticaria—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Prochlorperazine—Body temperature increased—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Prochlorperazine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000954	0.000954	CcSEcCtD
Prochlorperazine—Pruritus—Methotrexate—lymphatic system cancer	0.000916	0.000916	CcSEcCtD
Prochlorperazine—Dizziness—Methotrexate—lymphatic system cancer	0.000856	0.000856	CcSEcCtD
Prochlorperazine—Rash—Methotrexate—lymphatic system cancer	0.000816	0.000816	CcSEcCtD
Prochlorperazine—Dermatitis—Methotrexate—lymphatic system cancer	0.000816	0.000816	CcSEcCtD
Prochlorperazine—Headache—Methotrexate—lymphatic system cancer	0.000811	0.000811	CcSEcCtD
